The cardiorenal nutrition products market is expected to grow from USD 152.1 million in 2026 to USD 350.2 million by 2036, representing a compound annual growth rate (CAGR) of 8.7%. This growth is driven by a rising demand for specialized nutrition products due to increasing instances of kidney dysfunction alongside heart complications.

Read More

As highlighted in a report by Future Market Insights (FMI), the need for cardiorenal nutrition products stems from the requirement for nutritional support that does not exacerbate sodium, potassium, or fluid intake for patients with overlapping health issues. According to the Centers for Disease Control and Prevention, around 35.5 million adults in the U.S. were living with chronic kidney disease in 2026, often with concurrent cardiovascular complications. This has prompted the development of products specifically tailored to manage dietary restrictions in such patients.

The demand for these products exhibits diverse trends across different countries, depending on patient demographics, screening practices, and care pathways. South Korea is projected to experience an 8.8% CAGR due to increased chronic kidney disease (CKD) surveillance and a significant elderly population. The UK is expected to grow at 8.4% CAGR, benefiting from comprehensive cardiovascular and kidney care frameworks.

In terms of market segmentation, low-sodium low-potassium dual-adapted oral nutrition supplements (ONS) are anticipated to capture 47.5% of the market in 2026, as they efficiently cover multiple dietary restrictions. Meanwhile, the heart failure with CKD segment is expected to hold a 47.0% share, reflecting the intertwined management of fluid balance and renal health.

Ready-to-drink (RTD) formats are forecasted to dominate product forms with a 41.8% market share, owing to their convenience and consistency in nutritional delivery. Hospitals are projected to remain the primary end users, accounting for 39.7% of the market share, facilitating multidisciplinary assessments to ensure appropriate product selection.

Key players in the cardiorenal nutrition market include Abbott, Fresenius Kabi, Nestle Health Science, and Danone Nutricia, among others. Their focus is increasingly on products that offer precise electrolytic content and support for managing both renal and cardiac health effectively.